<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of nontuberculous mycobacterial infections</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of nontuberculous mycobacterial infections</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of nontuberculous mycobacterial infections</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David E Griffith, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Fordham von Reyn, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 23, 2020.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Nontuberculous mycobacteria (NTM) species are mycobacterial species other than those belonging to the <em>Mycobacterium tuberculosis</em> complex (eg, <em>M. tuberculosis</em>, <em>Mycobacterium bovis</em>, <em>Mycobacterium africanum</em>, and <em>Mycobacterium microti</em>) and <em>Mycobacterium leprae</em>. NTM are generally free-living organisms that are ubiquitous in the environment. Molecular identification techniques, including whole-genome sequencing, have identified approximately 200 NTM species.</p><p>An overview of NTM infection in HIV-negative patients, with emphasis on chronic lung infections that account for up to 90 percent of patient encounters due to NTM, will be reviewed here. The epidemiology, microbiology, pathogenesis, diagnosis, and treatment of NTM infection, as well as infection due to rapidly growing mycobacteria and <em>M. ulcerans</em>, are discussed separately. (See  <a class="medical medical_review" href="/d/html/5344.html" rel="external">"Epidemiology of nontuberculous mycobacterial infections"</a> and  <a class="medical medical_review" href="/d/html/5343.html" rel="external">"Microbiology of nontuberculous mycobacteria"</a> and  <a class="medical medical_review" href="/d/html/5345.html" rel="external">"Pathogenesis of nontuberculous mycobacterial infections"</a> and  <a class="medical medical_review" href="/d/html/5346.html" rel="external">"Diagnosis of nontuberculous mycobacterial infections of the lungs"</a> and  <a class="medical medical_review" href="/d/html/5341.html" rel="external">"Treatment of <i>Mycobacterium avium </i>complex pulmonary infection in adults"</a> and  <a class="medical medical_review" href="/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum"</a> and  <a class="medical medical_review" href="/d/html/5349.html" rel="external">"Buruli ulcer (Mycobacterium ulcerans infection)"</a>.)</p><p>NTM infections in patients with HIV and lung transplant candidates and recipients are also reviewed separately. (See  <a class="medical medical_review" href="/d/html/3755.html" rel="external">"Mycobacterium avium complex (MAC) infections in persons with HIV"</a> and  <a class="medical medical_review" href="/d/html/3705.html" rel="external">"Overview of nontuberculous mycobacteria (excluding MAC) in patients with HIV"</a> and  <a class="medical medical_review" href="/d/html/1413.html" rel="external">"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H3005462569"><span class="h1">SPECTRUM OF CLINICAL SYNDROMES</span><span class="headingEndMark"> — </span>In broad terms, Nontuberculous mycobacteria (NTM) can cause four clinical syndromes in humans [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary disease, especially in older persons with or without underlying lung disease and patients with cystic fibrosis, caused primarily by <em>Mycobacterium avium</em> complex (MAC), <em>Mycobacterium abscessus</em> subsp <em>abscessus</em>, and <em>Mycobacterium kansasii</em>.</p><p></p><p class="bulletIndent1">Other species that cause lung disease include <em>Mycobacterium xenopi</em>, <em>Mycobacterium malmoense</em>, <em>Mycobacterium szulgai</em>, and <em>Mycobacterium simiae</em>  (<a class="graphic graphic_table graphicRef61936" href="/d/graphic/61936.html" rel="external">table 1</a>) [<a href="#rid3">3</a>]. Geography plays a prominent role in the epidemiology of NTM pulmonary disease. <em>M. xenopi</em> is relatively more common in Europe, Great Britain, and Canada, <em>M. simiae</em> is relatively more common in the Southwest United States and Israel, while <em>M. malmoense</em> is relatively more common in Scandinavia and Northern Europe [<a href="#rid1">1,4</a>]. (See  <a class="medical medical_review" href="/d/html/5344.html" rel="external">"Epidemiology of nontuberculous mycobacterial infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Superficial lymphadenitis, especially cervical lymphadenitis, in children caused mostly by MAC, <em>Mycobacterium scrofulaceum</em>, and, in Northern Europe, <em>M. malmoense</em> and <em>Mycobacterium haemophilum</em>. (See  <a class="medical medical_review" href="/d/html/14425.html" rel="external">"Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children"</a> and  <a class="medical medical_review" href="/d/html/86045.html" rel="external">"Nontuberculous mycobacterial lymphadenitis in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disseminated disease in severely immunocompromised patients (most commonly caused by MAC and less commonly by the rapidly growing mycobacteria [RGM], eg, <em>M. abscessus</em>, <em>M. fortuitum</em>, and <em>Mycobacterium chelonae</em>). (See  <a class="medical medical_review" href="/d/html/3755.html" rel="external">"Mycobacterium avium complex (MAC) infections in persons with HIV"</a> and  <a class="medical medical_review" href="/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin and soft tissue infection usually as a consequence of direct inoculation, caused primarily by <em>Mycobacterium marinum</em> and <em>Mycobacterium ulcerans</em>, the RGM, and other NTM species including MAC. RGM infections in this category may be nosocomial, including surgical site infections [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">MYCOBACTERIUM AVIUM COMPLEX</span><span class="headingEndMark"> — </span>The term <em>M. avium</em> complex (MAC) encompasses multiple species including <em>M. avium</em>, <em>Mycobacterium intracellulare</em>,<em> Mycobacterium</em> <em>chimaera, Mycobacterium</em> <em>colombiense, Mycobacterium</em> <em>arosiense, Mycobacterium</em> <em>marseillense, Mycobacterium</em> <em>timonense, Mycobacterium</em> <em>bouchedurhonense, Mycobacterium</em> <em>vulneris, </em>and<em> Mycobacterium</em> <em>yongonense.</em> These organisms are genetically similar and generally not differentiated in the clinical microbiology laboratory. Among nontuberculous mycobacteria (NTM), MAC (specifically <em>M. avium</em> and <em>M. intracellulare</em>) is the most common cause of pulmonary disease worldwide. (See  <a class="medical medical_review" href="/d/html/5343.html" rel="external">"Microbiology of nontuberculous mycobacteria"</a>.)</p><p>It is generally felt that these organisms are acquired from the environment. Mounting evidence suggests that municipal water sources may be an important source for MAC lung infections [<a href="#rid6">6-8</a>]. Unlike <em>M. tuberculosis</em>, there are no convincing data demonstrating human-to-human or animal-to-human transmission of MAC. (See  <a class="medical medical_review" href="/d/html/5344.html" rel="external">"Epidemiology of nontuberculous mycobacterial infections"</a>.)</p><p class="headingAnchor" id="H407656780"><span class="h2">Pulmonary disease</span></p><p class="headingAnchor" id="H3"><span class="h3">Clinical manifestations</span><span class="headingEndMark"> — </span>The symptoms and signs of MAC lung disease are variable, not specific, and are influenced by whether the patient has pre-existing symptomatic lung disease. They include cough (productive or dry), fatigue, malaise, weakness, dyspnea, chest discomfort, and occasionally hemoptysis. Fever and weight loss occur less frequently than in patients with typical tuberculosis. Examination of the lungs is often normal but, since these infections frequently coexist with underlying lung disease such as chronic obstructive pulmonary disease (COPD) or bronchiectasis [<a href="#rid9">9</a>], physical findings of the latter diseases may predominate.</p><p>Two major clinical presentations have been described:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease in those with known underlying lung disease</strong> – This occurs primarily in White, middle-aged or older men with a history of smoking and underlying chronic obstructive pulmonary disease. The disease resembles typical tuberculosis clinically and radiographically, with cough, weight loss, upper lobe infiltrates, and cavities [<a href="#rid10">10,11</a>]. Symptoms are generally less severe than those associated with tuberculosis. Additionally, due to the relatively indolent nature of MAC lung disease, lung destruction may be quite extensive at the time of diagnosis with very large cavities on chest radiograph. </p><p></p><p class="bulletIndent1">Another presentation is seen in patients in whom MAC develops in areas of prior bronchiectasis, such as patients with prior tuberculosis. Older adults are also affected, but there is no association with male sex or smoking-related pulmonary disease. Most commonly, patients with prior treated tuberculosis develop symptoms, such as cough, sputum production, fatigue and weight loss, and a new infiltrate in the previously affected lung zone suggesting a relapse of tuberculosis. This pattern is also seen with other types of bronchiectasis including cystic fibrosis [<a href="#rid11">11,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease in those without previously suspected or diagnosed lung disease</strong> – This occurs predominantly in nonsmoking women over age 50 who have abnormal chest radiography consistent with bronchiectasis [<a href="#rid9">9,13</a>]. Such patients usually experience many years of progressive respiratory symptoms and recurrent respiratory infections due to unrecognized underlying bronchiectasis. For many clinicians, this is the most commonly encountered form of MAC lung disease. The typical presenting symptoms are persistent cough with variable sputum production, sometimes with weight loss but usually without fever. In one report, the mean duration of cough was 25 weeks before the diagnosis was made [<a href="#rid9">9</a>], but some patients are symptomatic for many years prior to diagnosis. Previously thought to represent a relatively benign process, the serious nature of this disease has become increasingly evident. Patients with persistently positive sputum cultures for MAC experience worsening radiographic appearance, accelerated decline in pulmonary function testing, and increased mortality [<a href="#rid9">9,14,15</a>]. </p><p></p><p class="bulletIndent1">Radiographically, this form of MAC lung disease is invariably associated with multiple small nodules and cylindrical bronchiectasis (often in the mid-lung fields) and is referred to as nodular/bronchiectatic MAC lung disease [<a href="#rid16">16</a>]. A syndrome of right middle lobe or lingular infiltrates, sometimes called the Lady Windermere syndrome, has been noted in older women without predisposing lung disease, volume loss, adenopathy, or cavitation [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1">Shedding of MAC into the respiratory secretions in these patients is less consistent than in the fibrocavitary form of the disease. Sputa may be intermittently positive and/or positive with low numbers of organisms. </p><p></p><p class="bulletIndent1">In a series of selected patients with this form of MAC lung disease, it was noted that they tend to be taller and leaner than control subjects and have increased likelihood of pectus excavatum, scoliosis, and mitral valve prolapse [<a href="#rid17">17,18</a>]. These patients are also more likely to have cystic fibrosis transmembrane conductance regulator mutations in the absence of recognized immune defects [<a href="#rid18">18</a>]. There were no consistent or severe immune defects such as cell-mediated immune dysfunction or cytokine pathway abnormalities identified in these patients. The pathophysiologic consequences of the morphologic abnormalities and their potential contribution(s) to the predisposition for MAC infection are not yet known. While there is no clear single genetic mutation to explain this association, it has been suggested that several genetic variants predispose to MAC lung disease [<a href="#rid19">19,20</a>]. (See  <a class="medical medical_review" href="/d/html/5345.html" rel="external">"Pathogenesis of nontuberculous mycobacterial infections", section on 'Nodular/bronchiectatic disease'</a>.) </p><p></p><p>Two other less common forms of MAC lung disease have been described:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Solitary pulmonary nodules</strong> – One report noted an unexpectedly high frequency (78 of 244 patients) of MAC pulmonary infections presenting as solitary pulmonary nodules, which resembled lung cancer [<a href="#rid11">11</a>]. Solitary pulmonary nodules caused by MAC were observed in 11 patients in South Korea in a retrospective study [<a href="#rid21">21</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersensitivity pneumonitis</strong> – MAC exposure in immunocompetent hosts without underlying lung disease has been linked to the development of hypersensitivity pneumonitis, particularly following hot tub use [<a href="#rid22">22-25</a>]. The resulting hypersensitivity reaction ("hot tub lung") generally responds to avoidance of the offending environment, and the role of antibiotic therapy appears limited. (See  <a class="medical medical_review" href="/d/html/4309.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Epidemiology, causes, and pathogenesis", section on 'Ventilation and water-related contamination'</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h3">Diagnostic criteria</span><span class="headingEndMark"> — </span>Diagnostic criteria for nontuberculous mycobacterial pulmonary infections include compatible symptoms, imaging studies consistent with pulmonary disease, and recurrent isolation (from at least two specimens) of mycobacteria from sputum or isolation of mycobacteria from at least one bronchial wash in a symptomatic patient  (<a class="graphic graphic_table graphicRef61404" href="/d/graphic/61404.html" rel="external">table 2</a>) [<a href="#rid2">2,26</a>]. (See  <a class="medical medical_review" href="/d/html/5346.html" rel="external">"Diagnosis of nontuberculous mycobacterial infections of the lungs"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Disseminated disease</span><span class="headingEndMark"> — </span>Disseminated MAC disease may complicate MAC pulmonary disease through local multiplication and entry into the bloodstream with seeding of other organs and tissues. The disease primarily occurs in severely immunocompromised patients, such as those with advanced HIV infection, hematologic malignancy, or a history of immunosuppressive therapy including therapy with tumor necrosis alpha inhibitors [<a href="#rid27">27-29</a>]. (See  <a class="medical medical_review" href="/d/html/5344.html" rel="external">"Epidemiology of nontuberculous mycobacterial infections", section on 'Disseminated disease'</a>.)</p><p>Disseminated disease following exposure to contaminated equipment used in cardiac surgery has also been described. (See <a class="local">'M. chimaera associated with cardiac surgery'</a> below.)</p><p class="headingAnchor" id="H7"><span class="h3">Clinical symptoms and signs</span><span class="headingEndMark"> — </span>Clinically, disseminated MAC manifests as intermittent or persistent fever (&gt;80 percent), night sweats (&gt;35 percent), weight loss (&gt;25 percent), with additional symptoms including fatigue, malaise, and anorexia [<a href="#rid28">28</a>]. Organ-specific symptoms and signs reflect the major sites of involvement including anemia and neutropenia from bone marrow involvement; adenopathy or hepatosplenomegaly from lymphoreticular involvement; diarrhea, abdominal pain, hepatomegaly, and elevations of liver enzymes from involvement of the gastrointestinal tract; and cough and lung infiltrates from pulmonary involvement.</p><p class="headingAnchor" id="H8"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis is most readily established by culture of blood for mycobacteria. It is important to note that mycobacterial blood cultures are collected in special media, different from the media used in standard bacterial blood cultures, and must be specifically requested. Mycobacterial cultures must be specifically requested so that the cultures are not discarded before there has been time to detect mycobacterial growth. Although mycobacterial growth can sometimes be detected as early as a few days after obtaining the culture, in general, mycobacterial cultures cannot be confidently deemed negative until six weeks have passed without growth.</p><p>Specimens from bone marrow, or fluid or tissue from suspected sites of involvement should also be submitted for culture and histopathology. Noncaseating granulomas on pathology are supportive of mycobacterial involvement. Bacillary forms may be visible on acid-fast staining, but their absence does not rule out the possibility of infection.</p><p>Although molecular testing has been used for epidemiological investigation, such techniques are generally not clinically available. </p><p class="headingAnchor" id="H1111710550"><span class="h3">Management</span><span class="headingEndMark"> — </span>Limited data are available to guide management of disseminated MAC in patients without HIV infection. Medical therapy typically consists of several antimycobacterial agents for at least several months. Correction of immunosuppression is also essential for an optimal response to therapy. Patients with disseminated disease may also require adjunctive surgical intervention (eg, valve replacement, joint replacement, or debridement of infected bone) for clinical cure.</p><p>For patients with macrolide-susceptible disease, a multidrug regimen similar to that used for pulmonary MAC disease (ie, a macrolide plus <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> plus a rifamycin) is generally used. Patients with extensive, severe, or life-threatening disease should also receive a parenteral aminoglycoside, such as <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a>, during the initial 8 to 12 weeks of therapy, although even longer periods of parenteral therapy may be required. </p><p>If the isolate is macrolide-resistant, therapy consists of <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> plus a rifamycin, preferably <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>, plus a parenteral aminoglycoside. The addition of another antimycobacterial agent, such as <a class="drug drug_general" data-topicid="107872" href="/d/drug information/107872.html" rel="external">clofazimine</a>, may also be of some value, although there are few data supporting its use in this setting. The fluoroquinolones have no demonstrated activity or value in this setting.</p><p>Oral agents are administered daily. Parenteral aminoglycosides (eg, <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a>) are administered three to five times weekly. (See  <a class="medical medical_review" href="/d/html/5341.html" rel="external">"Treatment of <i>Mycobacterium avium </i>complex pulmonary infection in adults", section on 'Regimen selection'</a>.)</p><p>The optimal duration of treatment has not been established, but treatment is usually administered for at least six months. The precise duration depends on the underlying cause or predisposition for the disseminated MAC infection. As an example, for patients with easily remediable sources of MAC dissemination (ie, without a sequestered site of infection), six months of therapy may be adequate. In contrast, for patients with MAC infections in areas where antibiotic penetration is suboptimal, such as bone or joints, 12 months of therapy is likely necessary for cure. Similarly, for those patients with underlying immunosuppression, the duration of therapy depends on the severity and reversibility of the immune deficits. For patients with reversible or temporary immunosuppression, treatment duration is similar to that for patients with HIV and disseminated MAC who recover immune function (ie, at least 12 months of treatment with at least six months of immune reconstitution). For patients with persistent and severe immunosuppression, the adequate duration of therapy is not established, and may be open ended. (See  <a class="medical medical_review" href="/d/html/3755.html" rel="external">"Mycobacterium avium complex (MAC) infections in persons with HIV", section on 'Duration of MAC therapy'</a>.)</p><p>One difficult aspect of treating extra-pulmonary MAC infection is the lack of diagnostic tools to measure treatment outcome. Whereas sputum AFB cultures and chest radiographic studies are relatively easy to obtain and follow to evaluate a patient's response to therapy for pulmonary MAC disease, obtaining sequential cultures may be essentially impossible for many extra-pulmonary sites. The reliability of sequential imaging for sites such as bone and joints is also not established. (See  <a class="medical medical_review" href="/d/html/13995.html" rel="external">"Treatment of osteomyelitis due to nontuberculous mycobacteria in adults", section on 'Monitoring during therapy'</a>.)</p><p class="headingAnchor" id="H3016096324"><span class="h2">M. chimaera associated with cardiac surgery</span><span class="headingEndMark"> — </span><em>Mycobacterium chimaera</em> is a MAC species that has generally been thought to have relatively low virulence, at least as a pulmonary pathogen. Two prolonged outbreaks of <em>M. chimaera</em> prosthetic valve infections and associated disseminated infection, in which the source was determined through epidemiologic and molecular analysis to be the heater-cooler unit used for cardiac bypass procedures, were first described in 2015 in Europe and the United States [<a href="#rid30">30,31</a>], and subsequent clusters have been reported elsewhere [<a href="#rid32">32,33</a>]. Molecular testing further suggested that the source of contamination of the implicated heater-cooler devices (Stockert 3T) was the manufacturing facility itself [<a href="#rid34">34</a>]. In the United States, the Food and Drug Administration and Centers for Disease Control and Prevention have made several recommendations to try to lower the risk of additional infections [<a href="#rid35">35,36</a>]. These include removing from service any Stockert 3T heater-cooler device that has tested positive for <em>M. chimaera</em> or that has been associated with known <em>M. chimaera</em> infections, replacing accessories and connectors that were used with such devices, and refraining from using any 3T heater-cooler device manufactured before September 2014 except in emergent situations when no other device is available. These infections can also be avoided by physically removing heater-cooler devices from the operating room. Testing of devices to identify contamination is not recommended because of technical challenges and a high rate of false-negative tests. </p><p>Although the risk is low, providers of patients who have undergone cardiac surgery should be aware of the possibility of <em>M. chimaera</em> infection if they develop signs and symptoms compatible with disseminated mycobacterial disease (eg, persistent fever, night sweats, weight loss). The majority of the patients described in the outbreaks presented with prosthetic valve endocarditis accompanied by other signs of disseminated disease including ocular emboli, bony involvement (eg, vertebral osteomyelitis), splenomegaly, pancytopenia, hepatitis, and renal impairment [<a href="#rid30">30,31,33,37</a>]. Other cases have involved surgical site infection. Patients presented months to years following the surgical procedure. Patients who have a presentation compatible with disseminated <em>M. chimaera</em> infection should have several mycobacterial blood cultures; depending on the clinical presentation, specimens from other sites should also be collected for microbiological and pathological testing [<a href="#rid38">38</a>]. (See <a class="local">'Clinical symptoms and signs'</a> above and <a class="local">'Diagnosis'</a> above.) </p><p>Treatment of the prosthetic valve and disseminated <em>M. chimaera</em> infections requires combined medical and surgical approaches. <em>M. chimaera</em> appears to be similar to other MAC species with regard to antibiotic responses and should be treated with the same macrolide-based regimens as other MAC species such as <em>M. avium</em> and <em>M. intracellulare</em>. However, similar to other MAC species, treatment success is not guaranteed with macrolide-based therapy. (See <a class="local">'Management'</a> above.)</p><p>This outbreak is unusual from many perspectives but especially with regards to the causative organism, which had traditionally been thought of as having low virulence. There is also no precedent for a similar outbreak of nosocomial mycobacterial prosthetic valve endocarditis. The reason that this pathogen has manifest now with this clinical presentation is unknown. Nevertheless, the relatively rapid identification of an unusual pathogen as the cause of a nosocomial outbreak and the identification of the environmental source of the infecting organism is a testament to the utility of molecular epidemiologic techniques for mycobacteria [<a href="#rid39">39</a>]. </p><p class="headingAnchor" id="H9"><span class="h1">MYCOBACTERIUM KANSASII</span><span class="headingEndMark"> — </span>Unlike other NTM, <em>M. kansasii</em> has never been found in soil or natural water supplies but has been recovered consistently from tap water in cities where <em>M. kansasii</em> is endemic. Thus, there appears to be an association between clinical disease and potable water supplies. (See  <a class="medical medical_review" href="/d/html/5344.html" rel="external">"Epidemiology of nontuberculous mycobacterial infections", section on 'Mycobacterium kansasii'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span><em>M. kansasii</em> usually presents as lung disease that is nearly identical to tuberculosis, although fever may be less common [<a href="#rid13">13</a>]. In older studies, cavitation occurred in 85 to 95 percent of cases, being bilateral in 20 percent [<a href="#rid10">10,40,41</a>]. In some cases, the cavities tended to have thinner walls and less surrounding parenchymal infiltration than in tuberculosis [<a href="#rid10">10,41</a>].</p><p>A survey of 56 adults with <em>M. kansasii</em> pulmonary infection in Israel diagnosed in the time period 1999 to 2004 noted the following findings [<a href="#rid42">42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The most common clinical presentations were chest pain (82 percent), cough (84 percent), hemoptysis (38 percent), fever, and night sweats (39 percent).</p><p class="bulletIndent1"><span class="glyph">●</span>Cavitation occurred in 54 percent.</p><p></p><p>The explanation for the difference in prevalence of cavitation in the studies is unclear, although patients in older studies may have had more advanced disease prior to diagnosis.</p><p>Disseminated infection is a rare complication that occurs in immunocompromised hosts such as those with HIV infection. (See  <a class="medical medical_review" href="/d/html/3705.html" rel="external">"Overview of nontuberculous mycobacteria (excluding MAC) in patients with HIV", section on 'Mycobacterium kansasii'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The same diagnostic criteria apply to the diagnosis of pulmonary infection with <em>M. kansasii</em> as to MAC infection. (See  <a class="medical medical_review" href="/d/html/5346.html" rel="external">"Diagnosis of nontuberculous mycobacterial infections of the lungs"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">RAPIDLY GROWING MYCOBACTERIA</span><span class="headingEndMark"> — </span>Rapidly growing mycobacteria (RGM) include three clinically relevant species: <em>M. abscessus </em>(including three subspecies:<em> abscessus</em>,<em> massiliense</em>,<em> </em>and<em> bolletii</em>),<em> M. fortuitum</em>, and <em>M. chelonae</em>  (<a class="graphic graphic_table graphicRef61936" href="/d/graphic/61936.html" rel="external">table 1</a>). The RGM are environmental organisms found worldwide that usually grow in culture in less than one week following initial isolation, and may sometimes grow on standard microbiologic media (rather than requiring special mycobacterial media). Pulmonary disease due to rapidly growing mycobacteria (RGM) is predominantly due to <em>M. abscessus</em> subsp <em>abscessus</em> and subsp <em>massiliense </em>and,<em> </em>less commonly, subsp <em>bolletii</em>. <em>M. fortuitum</em> and <em>M. chelonae</em> are rarely associated with lung disease. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum", section on 'Pulmonary infection'</a>.)</p><p>As noted above, disseminated NTM disease usually occurs in the immunosuppressed host. Perhaps surprisingly, <em>M. abscessus</em> is not an important pathogen in patients with HIV. However, in 2000, a previously unrecognized clinical entity of disseminated infection following lymphadenitis was reported in a group of 19 patients from northeast Thailand without HIV [<a href="#rid43">43</a>]. A follow-up report from this region in 2007 described 129 patients with chronic lymphadenitis and subsequent progressive involvement of other organs (eg, skin and soft tissue, lung, bone and joint, liver); 99 of 129 cases involved RGM [<a href="#rid44">44</a>]. Almost half of the patients also had other opportunistic infections, consistent with an underlying T-cell defect. In a subsequent study that included patients in Thailand and Taiwan who did not have HIV but had disseminated NTM (with both slow and rapidly growing species) or other opportunistic infections, the majority had neutralizing anti-interferon gamma autoantibodies [<a href="#rid45">45</a>]. There are only rare patients with a similar syndrome reported in the United States or Western Europe. Evaluation for neutralizing anti-interferon gamma autoantibodies should be performed in patients with disseminated NTM disease and no apparent predisposing risk factor. </p><p>RGM occasionally cause skin and soft tissue infections. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum", section on 'Skin and soft tissue infection'</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">OTHER NONTUBERCULOUS MYCOBACTERIA</span><span class="headingEndMark"> — </span>Other pathogens including <em>M. xenopi</em>, <em>M. simiae</em>, <em>M. szulgai</em>, and <em>M. malmoense</em> can also cause chronic lung disease  (<a class="graphic graphic_table graphicRef61936" href="/d/graphic/61936.html" rel="external">table 1</a>) [<a href="#rid3">3,46</a>]. The clinical manifestations and diagnostic criteria for infection are as discussed above for MAC. (See <a class="local">'Mycobacterium avium complex'</a> above.)</p><p class="headingAnchor" id="H3033057393"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113062.html" rel="external">"Society guideline links: Nontuberculous mycobacteria"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Nontuberculous mycobacteria (NTM) species are mycobacterial species other than those belonging to the <em>Mycobacterium tuberculosis</em> complex and <em>Mycobacterium leprae</em>. NTM are generally free-living organisms that are ubiquitous in the environment. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary disease, especially in older persons with or without underlying lung disease, is caused primarily by <em>Mycobacterium avium</em> complex (MAC), <em>Mycobacterium abscessus</em> subsp <em>abscessus</em>, and <em>Mycobacterium kansasii</em>. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among NTM, MAC is the most common cause of pulmonary disease worldwide. (See <a class="local">'Mycobacterium avium complex'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The symptoms and signs of MAC lung disease are variable and not specific, but include cough (productive or dry), fatigue, malaise, weakness, dyspnea, chest discomfort, and occasionally hemoptysis. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two major clinical presentations of MAC pulmonary disease include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cavitary disease in patients with underlying lung disease who are primarily White, middle-aged or older men, smokers with underlying chronic obstructive lung disease or in patients in whom MAC develops in areas of prior bronchiectasis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nodular/bronchiectatic disease in patients without previously diagnosed lung disease, including nonsmoking women over age 50 who invariably have bronchiectasis on chest radiography. In retrospect, these patients almost invariably have chronic respiratory symptoms, primarily cough, and recurrent respiratory infections. The presence of bronchiectasis is an important NTM lung disease predisposition regardless of the etiology, such as cystic fibrosis and pulmonary ciliary dyskinesia. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The American Thoracic Society and Infectious Disease Society of America's diagnostic criteria for nontuberculous mycobacterial pulmonary infections include both imaging studies consistent with pulmonary disease and recurrent isolation of mycobacteria from sputum or isolated from at least one bronchial wash in a symptomatic patient. (See  <a class="medical medical_review" href="/d/html/5346.html" rel="external">"Diagnosis of nontuberculous mycobacterial infections of the lungs"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unlike other NTM, <em>M. kansasii</em> has never been found in soil or natural water supplies, but has been recovered consistently from tap water in cities where <em>M. kansasii</em> is endemic. (See <a class="local">'Mycobacterium kansasii'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>M. kansasii</em> usually presents as lung disease that is nearly identical to tuberculosis. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary disease due to rapidly growing mycobacteria (RGM) is predominantly due to <em>Mycobacterium abscessus</em> (80 percent of cases) and <em>Mycobacterium fortuitum</em> (15 percent of cases). (See <a class="local">'Rapidly growing mycobacteria'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979; 119:107.</a></li><li><a class="nounderline abstract_t">Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.</a></li><li><a class="nounderline abstract_t">Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 1997; 156:S1.</a></li><li><a class="nounderline abstract_t">Wolinsky E, Rynearson TK. Mycobacteria in soil and their relation to disease-associated strains. Am Rev Respir Dis 1968; 97:1032.</a></li><li><a class="nounderline abstract_t">Phillips MS, von Reyn CF. Nosocomial infections due to nontuberculous mycobacteria. Clin Infect Dis 2001; 33:1363.</a></li><li><a class="nounderline abstract_t">Mullis SN, Falkinham JO 3rd. Adherence and biofilm formation of Mycobacterium avium, Mycobacterium intracellulare and Mycobacterium abscessus to household plumbing materials. J Appl Microbiol 2013; 115:908.</a></li><li><a class="nounderline abstract_t">Wallace RJ Jr, Iakhiaeva E, Williams MD, et al. Absence of Mycobacterium intracellulare and presence of Mycobacterium chimaera in household water and biofilm samples of patients in the United States with Mycobacterium avium complex respiratory disease. J Clin Microbiol 2013; 51:1747.</a></li><li><a class="nounderline abstract_t">Falkinham JO 3rd. Reducing human exposure to Mycobacterium avium. Ann Am Thorac Soc 2013; 10:378.</a></li><li><a class="nounderline abstract_t">Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321:863.</a></li><li><a class="nounderline abstract_t">Ahn CH, McLarty JW, Ahn SS, et al. Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare. Am Rev Respir Dis 1982; 125:388.</a></li><li><a class="nounderline abstract_t">Teirstein AS, Damsker B, Kirschner PA, et al. Pulmonary infection with Mycobacterium avium-intracellulare: diagnosis, clinical patterns, treatment. Mt Sinai J Med 1990; 57:209.</a></li><li><a class="nounderline abstract_t">Kilby JM, Gilligan PH, Yankaskas JR, et al. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 1992; 102:70.</a></li><li><a class="nounderline abstract_t">Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 1992; 101:1605.</a></li><li><a class="nounderline abstract_t">Park HY, Jeong BH, Chon HR, et al. Lung Function Decline According to Clinical Course in Nontuberculous Mycobacterial Lung Disease. Chest 2016; 150:1222.</a></li><li><a class="nounderline abstract_t">Park TY, Chong S, Jung JW, et al. Natural course of the nodular bronchiectatic form of Mycobacterium Avium complex lung disease: Long-term radiologic change without treatment. PLoS One 2017; 12:e0185774.</a></li><li><a class="nounderline abstract_t">Swensen SJ, Hartman TE, Williams DE. Computed tomographic diagnosis of Mycobacterium avium-intracellulare complex in patients with bronchiectasis. Chest 1994; 105:49.</a></li><li><a class="nounderline abstract_t">Iseman MD, Buschman DL, Ackerson LM. Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 1991; 144:914.</a></li><li><a class="nounderline abstract_t">Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008; 178:1066.</a></li><li><a class="nounderline abstract_t">Szymanski EP, Leung JM, Fowler CJ, et al. Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease. Am J Respir Crit Care Med 2015; 192:618.</a></li><li><a class="nounderline abstract_t">Chen F, Szymanski EP, Olivier KN, et al. Whole-Exome Sequencing Identifies the 6q12-q16 Linkage Region and a Candidate Gene, TTK, for Pulmonary Nontuberculous Mycobacterial Disease. Am J Respir Crit Care Med 2017; 196:1599.</a></li><li><a class="nounderline abstract_t">Lim J, Lyu J, Choi CM, et al. Non-tuberculous mycobacterial diseases presenting as solitary pulmonary nodules. Int J Tuberc Lung Dis 2010; 14:1635.</a></li><li><a class="nounderline abstract_t">Cappelluti E, Fraire AE, Schaefer OP. A case of "hot tub lung" due to Mycobacterium avium complex in an immunocompetent host. Arch Intern Med 2003; 163:845.</a></li><li><a class="nounderline abstract_t">Khoor A, Leslie KO, Tazelaar HD, et al. Diffuse pulmonary disease caused by nontuberculous mycobacteria in immunocompetent people (hot tub lung). Am J Clin Pathol 2001; 115:755.</a></li><li><a class="nounderline abstract_t">Kahana LM, Kay JM, Yakrus MA, Waserman S. Mycobacterium avium complex infection in an immunocompetent young adult related to hot tub exposure. Chest 1997; 111:242.</a></li><li><a class="nounderline abstract_t">Embil J, Warren P, Yakrus M, et al. Pulmonary illness associated with exposure to Mycobacterium-avium complex in hot tub water. Hypersensitivity pneumonitis or infection? Chest 1997; 111:813.</a></li><li><a class="nounderline abstract_t">Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 2020; 71:e1.</a></li><li><a class="nounderline abstract_t">Horsburgh CR Jr, Mason UG 3rd, Farhi DC, Iseman MD. Disseminated infection with Mycobacterium avium-intracellulare. A report of 13 cases and a review of the literature. Medicine (Baltimore) 1985; 64:36.</a></li><li><a class="nounderline abstract_t">Nightingale SD, Byrd LT, Southern PM, et al. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165:1082.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013; 72:37.</a></li><li><a class="nounderline abstract_t">Kohler P, Kuster SP, Bloemberg G, et al. Healthcare-associated prosthetic heart valve, aortic vascular graft, and disseminated Mycobacterium chimaera infections subsequent to open heart surgery. Eur Heart J 2015; 36:2745.</a></li><li><a class="nounderline abstract_t">Sax H, Bloemberg G, Hasse B, et al. Prolonged Outbreak of Mycobacterium chimaera Infection After Open-Chest Heart Surgery. Clin Infect Dis 2015; 61:67.</a></li><li><a class="nounderline abstract_t">Williamson D, Howden B, Stinear T. Mycobacterium chimaera Spread from Heating and Cooling Units in Heart Surgery. N Engl J Med 2017; 376:600.</a></li><li><a class="nounderline abstract_t">Chand M, Lamagni T, Kranzer K, et al. Insidious Risk of Severe Mycobacterium chimaera Infection in Cardiac Surgery Patients. Clin Infect Dis 2017; 64:335.</a></li><li><a class="nounderline abstract_t">Perkins KM, Lawsin A, Hasan NA, et al. Notes from the Field: Mycobacterium chimaera Contamination of Heater-Cooler Devices Used in Cardiac Surgery - United States. MMWR Morb Mortal Wkly Rep 2016; 65:1117.</a></li><li class="breakAll">UPDATE: Mycobacterium chimaera Infections Associated with LivaNova PLC (formerly Sorin Group Deutschland GmbH) Stӧckert 3T Heater-Cooler System: FDA Safety Communication http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm520191.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery (Accessed on October 17, 2016).</li><li class="breakAll">CDC Advises Hospitals to Alert Patients at Risk from Contaminated Heater-Cooler Devices Used during Cardiac Surgery, October 13, 2016. https://emergency.cdc.gov/han/han00397.asp (Accessed on October 17, 2016).</li><li><a class="nounderline abstract_t">Scriven JE, Scobie A, Verlander NQ, et al. Mycobacterium chimaera infection following cardiac surgery in the United Kingdom: clinical features and outcome of the first 30 cases. Clin Microbiol Infect 2018; 24:1164.</a></li><li><a class="nounderline abstract_t">Marra AR, Diekema DJ, Edmond MB. Mycobacterium chimaera Infections Associated With Contaminated Heater-Cooler Devices for Cardiac Surgery: Outbreak Management. Clin Infect Dis 2017; 65:669.</a></li><li><a class="nounderline abstract_t">van Ingen J, Kohl TA, Kranzer K, et al. Global outbreak of severe Mycobacterium chimaera disease after cardiac surgery: a molecular epidemiological study. Lancet Infect Dis 2017; 17:1033.</a></li><li><a class="nounderline abstract_t">Johanson WG Jr, Nicholson DP. Pulmonary disease due to Mycobacterium Kansasii. An analysis of some factors affecting prognosis. Am Rev Respir Dis 1969; 99:73.</a></li><li><a class="nounderline abstract_t">Christensen EE, Dietz GW, Ahn CH, et al. Radiographic manifestations of pulmonary Mycobacterium kansasii infections. AJR Am J Roentgenol 1978; 131:985.</a></li><li><a class="nounderline abstract_t">Shitrit D, Baum GL, Priess R, et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Chest 2006; 129:771.</a></li><li><a class="nounderline abstract_t">Chetchotisakd P, Mootsikapun P, Anunnatsiri S, et al. Disseminated infection due to rapidly growing mycobacteria in immunocompetent hosts presenting with chronic lymphadenopathy: a previously unrecognized clinical entity. Clin Infect Dis 2000; 30:29.</a></li><li><a class="nounderline abstract_t">Chetchotisakd P, Kiertiburanakul S, Mootsikapun P, et al. Disseminated nontuberculous mycobacterial infection in patients who are not infected with HIV in Thailand. Clin Infect Dis 2007; 45:421.</a></li><li><a class="nounderline abstract_t">Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med 2012; 367:725.</a></li><li><a class="nounderline abstract_t">Majoor CJ, Schreurs AJ, Weers-Pothoff G. Mycobacterium xenopi infection in an immunosuppressed patient with Crohn's disease. Thorax 2004; 59:631.</a></li></ol></div><div id="topicVersionRevision">Topic 5342 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/369415" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nontuberculous mycobacteria and associated diseases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17277290" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9279284" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4870217" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mycobacteria in soil and their relation to disease-associated strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11550115" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Nosocomial infections due to nontuberculous mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23742161" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adherence and biofilm formation of Mycobacterium avium, Mycobacterium intracellulare and Mycobacterium abscessus to household plumbing materials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23536397" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Absence of Mycobacterium intracellulare and presence of Mycobacterium chimaera in household water and biofilm samples of patients in the United States with Mycobacterium avium complex respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23952861" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Reducing human exposure to Mycobacterium avium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2770822" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Infection with Mycobacterium avium complex in patients without predisposing conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7073107" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2247097" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pulmonary infection with Mycobacterium avium-intracellulare: diagnosis, clinical patterns, treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1623799" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nontuberculous mycobacteria in adult patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1600780" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27298072" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Lung Function Decline According to Clinical Course in Nontuberculous Mycobacterial Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28968457" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Natural course of the nodular bronchiectatic form of Mycobacterium Avium complex lung disease: Long-term radiologic change without treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8275782" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Computed tomographic diagnosis of Mycobacterium avium-intracellulare complex in patients with bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1928970" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703788" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26038974" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28777004" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Whole-Exome Sequencing Identifies the 6q12-q16 Linkage Region and a Candidate Gene, TTK, for Pulmonary Nontuberculous Mycobacterial Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21144251" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Non-tuberculous mycobacterial diseases presenting as solitary pulmonary nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12695276" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A case of "hot tub lung" due to Mycobacterium avium complex in an immunocompetent host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11345841" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Diffuse pulmonary disease caused by nontuberculous mycobacteria in immunocompetent people (hot tub lung).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996025" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mycobacterium avium complex infection in an immunocompetent young adult related to hot tub exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9118726" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pulmonary illness associated with exposure to Mycobacterium-avium complex in hot tub water. Hypersensitivity pneumonitis or infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32628747" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3880852" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Disseminated infection with Mycobacterium avium-intracellulare. A report of 13 cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1349906" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22523429" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mycobacterial diseases and antitumour necrosis factor therapy in USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26188001" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Healthcare-associated prosthetic heart valve, aortic vascular graft, and disseminated Mycobacterium chimaera infections subsequent to open heart surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25761866" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prolonged Outbreak of Mycobacterium chimaera Infection After Open-Chest Heart Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28177865" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mycobacterium chimaera Spread from Heating and Cooling Units in Heart Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27927870" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Insidious Risk of Severe Mycobacterium chimaera Infection in Cardiac Surgery Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27740609" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Notes from the Field: Mycobacterium chimaera Contamination of Heater-Cooler Devices Used in Cardiac Surgery - United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27740609" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Notes from the Field: Mycobacterium chimaera Contamination of Heater-Cooler Devices Used in Cardiac Surgery - United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27740609" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Notes from the Field: Mycobacterium chimaera Contamination of Heater-Cooler Devices Used in Cardiac Surgery - United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29803845" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Mycobacterium chimaera infection following cardiac surgery in the United Kingdom: clinical features and outcome of the first 30 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28430899" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Mycobacterium chimaera Infections Associated With Contaminated Heater-Cooler Devices for Cardiac Surgery: Outbreak Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28711585" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Global outbreak of severe Mycobacterium chimaera disease after cardiac surgery: a molecular epidemiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5762115" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pulmonary disease due to Mycobacterium Kansasii. An analysis of some factors affecting prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/104602" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Radiographic manifestations of pulmonary Mycobacterium kansasii infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537880" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10619729" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Disseminated infection due to rapidly growing mycobacteria in immunocompetent hosts presenting with chronic lymphadenopathy: a previously unrecognized clinical entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638188" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Disseminated nontuberculous mycobacterial infection in patients who are not infected with HIV in Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22913682" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Adult-onset immunodeficiency in Thailand and Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15223876" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mycobacterium xenopi infection in an immunosuppressed patient with Crohn's disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
